Biopharmaceutical CMO and CRO - Global Strategic Business Report

The global market for Biopharmaceutical CMO and CRO was estimated at US$35.1 Billion in 2024 and is projected to reach US$44.6 Billion by 2030, growing at a CAGR of 4.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Biopharmaceutical CMO and CRO market.

Global Biopharmaceutical CMO and CRO Market - Key Trends & Drivers Summarized

Why Is Outsourcing Becoming Critical in Biopharmaceutical Development?

The increasing complexity of biopharmaceutical development has made outsourcing to Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) an essential strategy for pharmaceutical companies worldwide. With biologics and biosimilars driving innovation in the healthcare sector, the demand for specialized expertise, infrastructure, and regulatory compliance capabilities is surging. CMOs and CROs offer scalable, cost-efficient, and technologically advanced solutions that enable pharmaceutical firms to expedite research, clinical trials, and production while maintaining quality standards. The rise of personalized medicine, coupled with stringent regulatory requirements, has further cemented the role of outsourcing in biopharmaceutical development. Additionally, the COVID-19 pandemic underscored the importance of agile and flexible manufacturing capabilities, prompting increased reliance on external contract service providers for vaccine and monoclonal antibody production. As companies continue to streamline operations and focus on core competencies, the role of CMOs and CROs in accelerating drug development timelines and reducing operational costs is becoming more pronounced.

How Are Technological Advancements Reshaping the CMO and CRO Landscape?

The adoption of cutting-edge technologies such as artificial intelligence (AI), machine learning, and automation is revolutionizing the biopharmaceutical CMO and CRO market. AI-powered predictive analytics and advanced bioinformatics are improving drug discovery, patient recruitment, and clinical trial efficiency. Robotics and continuous manufacturing techniques are enhancing the scalability and precision of biopharmaceutical production, reducing waste and operational bottlenecks. Furthermore, advancements in cell and gene therapy manufacturing have necessitated the need for specialized contract service providers equipped with state-of-the-art bioprocessing technologies. As the industry moves towards more complex biologics, including monoclonal antibodies, vaccines, and gene-modified therapies, CMOs and CROs are expanding their capabilities to include modular production facilities, single-use bioreactors, and digital twin technology for process optimization. This wave of innovation is not only increasing efficiency but also ensuring better compliance with evolving regulatory frameworks, thereby accelerating the commercialization of next-generation biopharmaceuticals.

What Market Trends Are Driving the Growth of Biopharmaceutical CMO and CRO Services?

Several macroeconomic and industry-specific trends are fueling the growth of the biopharmaceutical CMO and CRO market. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has escalated the demand for biologics, propelling pharmaceutical firms to outsource development and production. Additionally, the globalization of clinical trials has led to a surge in demand for CROs that can navigate complex regulatory landscapes across multiple regions. Emerging markets in Asia-Pacific, particularly China and India, are becoming key hubs for biopharmaceutical outsourcing due to cost advantages, skilled labor, and government incentives. Another significant trend is the consolidation within the CMO and CRO sectors, as larger players acquire smaller firms to expand their service portfolios and geographic reach. Furthermore, the increasing focus on sustainability and green chemistry is influencing contract manufacturers to adopt eco-friendly production processes, minimizing waste generation and energy consumption in biopharmaceutical production. The convergence of these factors is solidifying the role of contract service providers as indispensable partners in the pharmaceutical value chain.

What Are the Key Drivers Fueling the Growth of the Biopharmaceutical CMO and CRO Market?

The growth in the biopharmaceutical CMO and CRO market is driven by several factors, including rising demand for biologics, increasing R&D expenditures, and the shift toward flexible and scalable manufacturing solutions. Advances in bioprocessing technologies, such as perfusion bioreactors and single-use systems, are enabling contract manufacturers to optimize production efficiency and reduce time-to-market. Pharmaceutical companies are increasingly outsourcing early-stage research and clinical trials to CROs to gain access to specialized expertise in pharmacokinetics, toxicology, and regulatory compliance. The expanding pipeline of biosimilars and orphan drugs is also driving demand for contract services, as smaller biotech firms seek cost-effective and compliant production solutions. Additionally, the biopharmaceutical industry’s shift toward decentralized clinical trials and real-world data analytics is fostering partnerships with CROs equipped with digital health capabilities. As companies prioritize speed, agility, and cost efficiency, the demand for integrated CMO and CRO solutions will continue to rise, shaping the future of biopharmaceutical innovation and commercialization.

Report Scope

The report analyzes the Biopharmaceutical CMO and CRO market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product Type (Biologics Type, Biosimilars Type); Source Type (Mammalian Source, Non-Mammalian Source); Service Type (Contract Manufacturing Services, Process Development Services, Fill and Finish Operations, Analytical and QC Studies, Contract Manufacturing Services)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Biologics Type segment, which is expected to reach US$25.5 Billion by 2030 with a CAGR of a 5.0%. The Biosimilars Type segment is also set to grow at 2.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $9.6 Billion in 2024, and China, forecasted to grow at an impressive 7.6% CAGR to reach $9.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Biopharmaceutical CMO and CRO Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Biopharmaceutical CMO and CRO Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Biopharmaceutical CMO and CRO Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Baxter International Inc., Binex Co., Ltd., Biothrive Sciences, Boehringer Ingelheim GmbH and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 48 Featured):

• AbbVie Inc.
• Baxter International Inc.
• Binex Co., Ltd.
• Biothrive Sciences
• Boehringer Ingelheim GmbH
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Cummins, Inc.
• Eurofins Scientific SE
• Evotec SE
• FujiFilm Diosynth Biotechnologies U.S.A., Inc.
• ICON plc
• Jrs Pharma GmbH Co. KG
• KBI Biopharma
• Kemwell Biopharma Pvt., Ltd.
• Lonza Group Ltd.
• PAREXEL International Corporation
• ProBioGen AG
• Rentschler Biopharma SE
• Samsung BioLogics Co., Ltd.
• Sartorius AG
• Sterling Pharma Solutions
• Syneos Health
• Thermo Fisher Scientific, Inc.
• Toyobo Co., Ltd.
• WuXi AppTec Co., Ltd.
• WuXi Biologics

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry